Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Anixa Biosciences Inc (ANIX)

Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic PR Newswire - Mon Dec 15, 2025

SAN JOSE, Calif. , Dec. 15, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 3.11 (-2.51%)
Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants PR Newswire - Thu Dec 11, 2025

Vaccine Was Safe and Well Tolerated at the Maximum Tolerated Dose

ANIX : 3.11 (-2.51%)
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 PR Newswire - Wed Dec 10, 2025

SAN JOSE, Calif. , Dec. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 3.11 (-2.51%)
Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization PR Newswire - Mon Nov 17, 2025

SAN JOSE, Calif. , Nov. 17, 2025 /PRNewswire/ -- Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 3.11 (-2.51%)
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s PR Newswire - Wed Nov 12, 2025

Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000 U.S. Women in 2026

ANIX : 3.11 (-2.51%)
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 PR Newswire - Mon Nov 10, 2025

SAN JOSE, Calif. , Nov. 10, 2025 /PRNewswire/ --  Anixa Biosciences, Inc.  ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 3.11 (-2.51%)
Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic PR Newswire - Wed Nov 5, 2025

Completion of key step in IND transfer for upcoming Phase 2 breast cancer vaccine clinical trial

ANIX : 3.11 (-2.51%)
Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference PR Newswire - Thu Oct 23, 2025

SAN JOSE, Calif. , Oct. 23, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer,...

ANIX : 3.11 (-2.51%)
Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology PR Newswire - Mon Oct 20, 2025

Expands global intellectual property coverage in markets with high breast cancer incidence

ANIX : 3.11 (-2.51%)
Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial PR Newswire - Tue Oct 7, 2025

Final Clinical Visit Marks Major Milestone in First-in-Human Evaluation of Breast Cancer Vaccine

ANIX : 3.11 (-2.51%)

Barchart Exclusives

Why Cloudflare (NET) Stock Options Could Be Due for a Comeback Trade Barchart - 16 minutes ago
Although Cloudflare has struggled amid broader questions impacting the tech ecosystem, NET stock may surprisingly benefit from a reflexive swing higher. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot